Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Q2 2026 earnings

Reported August 13, 2026 · After market close

Revenue-
EPS-$2.34Miss by $0.06
EPS estimate-$2.28

Next report

Nov 13, 2026 (in 2 months)
Revenue estimate$1.9M
EPS estimate-$2.50

Financials

Q2 2026

Income statement

See full
Revenue--100%
Operating income-$32.1M-17.4%
Net income-$36.7M-27.9%
EPS (diluted)-$2.34-26.5%

Balance sheet

See full
Cash & equivalents$133.3M-28.5%
Total debt$181.6M+70.1%
Total equity-$53.0M-177%
Total assets$154.2M-27.3%

Cash flow

See full
Operating cash flow-$29.9M+0.1%
CapEx-—
Free cash flow-$29.9M+0.1%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$1.84B+365%
Enterprise value$1.89B+497%
P/S1,419×—

Returns & leverage

See full
Current ratio5.1×+0.1×

FAQ

When did Inhibrx Biosciences, Inc. report Q2 2026 earnings?
Inhibrx Biosciences, Inc. (INBX) reported Q2 2026 earnings on August 13, 2026 after market close.
What were Inhibrx Biosciences, Inc.'s Q2 2026 revenue and EPS?
Inhibrx Biosciences, Inc. reported revenue of - and eps of $-2.34 for Q2 2026.
Did Inhibrx Biosciences, Inc. beat estimates in Q2 2026?
EPS missed the consensus estimate of $-2.28 by $0.06.
How did Inhibrx Biosciences, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $1.3M a year earlier and eps declined 26.5% from $-1.85.
Where can I find Inhibrx Biosciences, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0002007919-26-000044) and the 10-Q periodic report (0002007919-26-000042) directly on SEC EDGAR. The filing index links above go to sec.gov.